Clinical Data

CSCR DME Other pathologies

 


 


 

> Other pathologies

     – IPCV

Idiopathic Polypoidal choroidal vasculopathy (IPCV) is a disease of the choroidal vasculature.

It is characterised by the presence of aneurysmal polypoidal lesions and branching vascular network, in the choroidal vasculature. This can lead to serous or haemorrhagic pigment epithelial detachment (PED), episodes of exudative retinal detachment and subretinal exudation and haemorrhage.

It is considered a variant of neovascular AMD.

IPCV is a relatively common in Asian and African American populations, affecting both sexes .

Evidence supports that:

  • Symptomatic patients with IPCV can have complete regression without severe vision loss with photodynamic therapy (PDT) and anti-VEGF treatment.
  • 577nm SubLiminal laser can be used to supplement treatment in IPCV cases with suboptimal response to anti-VEGF treatment.

Efficacy of SubLiminal laser in IPCV Aflibercept resistant cases
Saad Younis, MD

 


      – AMD

Age-related macular degeneration is the world’s leading cause of irreversible blindness among elderly people.

Atrophic AMD (Dry AMD) affects approximately 80-90% of individuals with AMD.

In early AMD, small white or yellowish deposits, called drusen, form on the retina, beneath the macula, causing it to deteriorate or degenerate over time.

Hard drusen are small, well-demarcated lesions and can be seen in the healthy, aging population.
Soft drusen are large and there borders are less well defined (cotton-ball’ like). They are generally pathologic and are not found in young, healthy populations.

There is currently no treatment for drusen, nevertheless it has been observed clinically that subthreshold laser could make drusen disappear and prevent the progression of the pathology.

Clinical studies are currently ongoing regarding this topic.

SubLiminal laser in macular diseases
Victor Chong, MD

 

> Clinical References

  1. Central serous chorioretinopathy: A review of epidemiology and pathophysiology.
    Gerald Liew MBBS PhD, Godfrey Quin Franzco PhD, Mark Gillies Franzco PhD and Samantha Fraser-Bell Franzco PhD (Save Sight Institute, and Centre for Vision Research, University of Sydney, Sydney Australia)
  2. Central serous chorioretinopathy Acta Ophthalmol., 86 (2008), pp. 126–145 Wang et al., 2008 M. Wang, I.C. Munch, P.W. Hasler, C. Prünte, M. Larsen
  3. Experience with nontreatment of central serous choroidopathy.
    Arch Ophthalmol 1974; 91: 247–250. Klein ML, Van Buskirk EM, Friedman E, Gragoudas E, Chandra S
  4. Long-term follow-up of central serous chorioretinopathy.
    Br J Ophthalmol 1984; 68:815–820.Gilbert CM, Owens SL, Smith PD, Fine SL
  5. Longterm follow-up of a prospective trial of argon laser photocoagulation in the treatment of central serous retinopathy.
    Br J Ophthalmol 1988; 72: 829–834. Ficker L, Vafidis G, While A, Leaver P
  6. Risk factors for recurrence of serous macular detachment in untreated patients with central serous chorioretinopathy.
    Ophthalmic Res 2011; 46:160–163. Fok AC, Chan PP, Lam DS, Lai TY.
  7. SubLiminal® Micropulse Laser (577 nm) Treatment in Chronic Central Serous Chorioretinopathy.
    Paula Scholz, Lebriz Ersoy, Camiel J.F. Boon, Sascha Fauser; Department of Ophthalmology, University Hospital of Cologne, Cologne , Germany; b Leiden University Medical Center, Leiden , The Netherlands
  8. SubLiminal® Micropulse Laser (577 nm) Treatment in Chronic Central Serous Chorioretinopathy.
    Paula Scholz, Lebriz Ersoy, Camiel J.F. Boon, Sascha Fauser; Department of Ophthalmology, University Hospital of Cologne, Cologne , Germany; b Leiden University Medical Center, Leiden , The Netherlands
  9. Global Prevalence and Major Risk Factors of Diabetic Retinopathy.
    Diabetes care 2012 10.2337/dc11-1909 – Yau JW, Rogers SL, Kawasaki R, et al.
  10. SubLiminal® Micropulse Laser Therapy for Retinal Disorders.
    Retina Today – Christine Kiire, MD; Sobha Sivaprasad, MD; and Victor Chong, MD
  11. The Short-term Efficacy of SubLiminal® Micropulse Yellow (577-nm) Laser Photocoagulation for Diabetic Macular Edema.
    Korean J Ophthalmol. 2014 Oct;28(5):379-85. doi: 10.3341/kjo.2014.28.5.379. Epub 2014 Sep 18. Kwon YH, Lee DK, Kwon OW.